Difference between revisions of "Cook N, et al. Br. J. Cancer (2018) cited as Ref 580 in DOI: 10.1038/s41392-020-0110-5 (Q9843)"
Jump to navigation
Jump to search
(Created claim: title (P93): A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma, #quickstatements; #temporary_batch_1590010982689) |
(Created claim: Page(s) (P105): 793-801, #quickstatements; #temporary_batch_1590074839150) |
||
| Property / Page(s) | |||
| + | 793-801 | ||
| Property / Page(s): 793-801 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Cook N, et al. Br. J. Cancer (2018) cited as Ref 580 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Cook N
0 references
2018
0 references
Br. J. Cancer
0 references
118
0 references
A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma (English)
0 references
793-801
0 references
